References

Below are references used in Macular Society publications.

Treatment for Macular Conditions, March 2016
1. Owen CG, Jarrar Z, Wormald R, et al. Br J Ophthalmol (2012). Doi: 1-.1136/bjophthalmol-2011-301109
2. RCOphth AMD Guidelines for Management 2013
3. RCOphth Statement: Choice of anti-VEGF agents for wet AMD treatment, Feb 2014
4. Chew EY, Clemons TE, Agrón E, et al. Long-Term Effects of Vitamins C, E, Beta-Carotene and Zinc on Age-Related Macular Degeneration. AREDS Report No. 35. Ophthalmology. 2013;120(8):1604-1611.e4. 
5. The Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA.2013;309(19):2005-2015. 

Nutrition and Eye Health, March 2016
1. Maiani, G. et al, 2009, ‘Carotenoids: Actual knowledge on food sources, intakes, stability and bioavailability  and their protective role in  humans’, Mol. Nutr. Food Res, vol 53, pp. 194-218
2. Tan, JSL et al, 2007, ‘Smoking and the long-term incidence of age-related macular degeneration: the blue mountains eye study’, Arch Ophthalmol, 125 (8), pp. 1089-1095
3. Chew EY, Clemons TE, Agrón E, et al. Long-Term Effects of Vitamins C, E, Beta-Carotene and Zinc on Age-Related Macular Degeneration. AREDS Report No. 35. Ophthalmology. 2013;120(8):1604-1611.e4. 
4. The Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA.2013;309(19):2005-2015. 

Diabetic Macular Oedema, February 2016

1. Al-Husainy, S. and Gibson, J.M.  Retina Today, 2014 April; pp75-76
2. NIHR HSC ID 4827 (May 2013) Aflibercept (Eylea) for visual impairment due to diabetic macular oedema  
3. Minassian D.C, Owens D.R, Reidy A,  Prevalence of diabetic macular oedema and related health and social care resource use in England.  
Br J Ophthalmol. 2012 Mar; 96(3):345-9. doi: 10.1136/bjo.2011.204040.
4. Royal College of Ophthalmology, Diabetic Retinopathy Guidelines, 2012. 
5. Your guide to diabetic eye screening, NHS  DES02
6. Yau, JW, et al. Global prevalence and major risk factors of diabetic retinopathy, Diabetes Care 2012;35: 556–564.
7. www.nhs.uk/Conditions/Diabetic-retinopathy/Pages/Introduction.aspx

Visual Hallucinations, February 2016

1. Cox TM, ffytche DH. Negative outcome Charles Bonnet syndrome. Br J Ophthalmol. 2014;98(9):1236-9.
2.ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nature Neurosci. 1998;1(8):738-42.

Protecting Your Eyes, January 2016

1. Loane E, Kelliher C, Beatty S, Nolan JM. The rationale and evidence base for a protective role of macular pigment in age-related maculopathy. British Journal of Ophthalmology 2008 Sep;92(9):1163-8.